# Safety and Effectiveness of an Investigational Agent (GM-611) in Patients With Diabetic Gastroparesis

> **NCT00050882** · PHASE2 · COMPLETED · sponsor: **Chugai Pharma USA**

## Conditions studied

- Gastroparesis

## Interventions

- **DRUG:** GM-611

## Key facts

- **NCT ID:** NCT00050882
- **Lead sponsor:** Chugai Pharma USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00050882

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00050882, "Safety and Effectiveness of an Investigational Agent (GM-611) in Patients With Diabetic Gastroparesis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00050882. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*